

# CUMULATIVE INDEX 1992

## Volume 12

---

March	LABORATORY IMMUNOLOGY I, pages 1-162
June	LABORATORY IMMUNOLOGY II, pages 163-392
September	REPRODUCTIVE MEDICINE AND THE CLINICAL LABORATORY, 393-654
December	SELECTED TOPICS IN TRANSFUSION MEDICINE, pages 655-836

---

Note: Page numbers of article titles are in **boldface** type

- ABO blood groups, determination of, for transfusion, 686-689  
hemolytic disease of newborn and, 556-559  
in parentage analysis, 621-625
- Abortion, immunologic mechanisms in, 557, 559
- Accident reports, in transfusion medicine, 837
- Acetylcholinesterase, measurement of, neural tube defects and, 485, 489
- Acid-base status, fetal, assessment of, 517-518
- Acidosis, in hemolytic disease of newborn, 564
- Acrosome reaction, of sperm, 414-415
- Actin-cytoskeleton, integrin interaction with, 223-224
- Acute lymphoblastic leukemia, minimal residual cells from, detection of, 139-145
- Acute myelogenous leukemia, minimal residual cells from, detection of, 145
- Adenosine deaminase deficiency, prenatal diagnosis of, 513
- Adhesion, cellular, integrins in. See *Integrins*.
- Adsorption filtration, of transfusion components, for microbial removal, 791-792
- Adult T-cell lymphoma-leukemia syndrome, flow cytometric analysis in, 262
- Alanyl tRNA synthetase, antibodies to, in polymyositis, 11
- Albumin, fetal. See *Alpha-fetoprotein*.  
in hemapheresis, 591, 593, 598-599
- Allele-specific oligonucleotide probes, in Tay-Sachs disease assessment, 472
- Alloantibody analysis, in hemolytic disease of newborn, 561-562
- Allograft rejection. See *Transplantation, rejection markers in*.
- Alloimmunization, to human leukocyte antigens, prevention of, in transfusion, 711-713  
to platelet antigens, neonatal thrombocytopenia in, 577-586  
to red cells. See *Hemolytic disease of newborn*.
- Allophycocyanin, in flow cytometry, 246
- Alpha-fetoprotein, isoforms of, 482  
levels of, in disease, 482-483  
measurement of, 481-492  
clinical uses of, 483-484  
diabetes mellitus and, 487  
drug ingestion and, 487-488  
gestational age and, 486  
in amniotic fluid, 488  
materials for, 484  
maternal weight and, 486-487  
methods for, 484-485  
multiple of median value in, 485-486  
multiple pregnancy and, 487  
racial factors in, 487  
results handling in, 485-489

- Alpha-fetoprotein (*Continued*)  
 physicochemical properties of, 481  
 American Association of Blood Banks,  
 legal issues in transfusion and, 819,  
 822, 825-826, 831
- Aminomethyl trimethyl psoralen  
 treatment, of transfusion  
 components, 796
- Amniocentesis, alpha-fetoprotein testing  
 and, 484, 488-489  
 in fetal lung maturity assessment, 603-  
 630  
 in granulomatous disease detection, 298  
 in prenatal diagnosis, 494-495  
 efficacy of, 500  
 hemolytic disease of newborn, 559-  
 561  
 Tay-Sachs disease, 469  
 toxoplasmosis, 508
- Amniotic fluid, surfactant in, 606-607
- Amplified fragment length  
 polymorphisms, in parentage  
 analysis, 633
- Androgens, assessment of, in infertility  
 evaluation, 398  
 in hemostasis, 776
- Anemia, aplastic, diagnosis of, molecular  
 probe techniques in, 115  
 hemolytic, in antiphospholipid antibody  
 syndrome, 45  
 in newborn. See *Hemolytic disease of  
 newborn*.  
 transfusion in, 655-656  
 alternatives to, 658  
 hemoglobin level trigger point and,  
 656-658
- Angelman syndrome, prenatal diagnosis  
 of, 498
- Antepartum nonstress test, in hemolytic  
 disease of newborn, 563
- Anti-immunoglobulin G reagent, in  
 antibody screening, for transfusion,  
 690
- Antibiotic treatment, of transfusion  
 components, 793-794
- Antibodies. See also *Autoantibodies*;  
 specific antibody, e.g.,  
*Antiphospholipid antibodies*.  
 antiphospholipid, in recurrent sponta-  
 neous miscarriage, 407  
 antisperm, detection of, 399-400, 402  
 in drug-induced lupus erythematosus,  
 8-9  
 monoclonal. See *Monoclonal antibodies*.  
 platelet, in transfusion, 663  
 testing for, in transfusion, 687-688,  
 690-692  
 to HIV. See under *Human immunodeficiency virus*.
- Antibody-dependent cell-mediated assay,  
 in hemolytic disease of newborn, 562
- Antibody-dependent cellular cytotoxicity,  
 in HIV infection, 317
- Anticardiolipin antibodies, familial, 43  
 in neurologic disease, 75  
 in recurrent spontaneous miscarriage,  
 407  
 incidence of, 42-43
- Anticoagulant(s), in antiphospholipid  
 antibody syndrome, 46-47  
 lupus. See *Lupus anticoagulant*.
- Antifibrinolytic agents, in hemostasis, 776
- Antigens. See also specific antigen, e.g.,  
*p24 antigen*.  
 alloimmunization to, prevention of, in  
 transfusion, 711-713  
 phenotyping of, 765  
 in HIV infection, 308, 310, 317-318  
 in rheumatic disease, autoantibodies to.  
 See under *Autoantibodies*.  
 platelet. See *Platelet antigens*.  
 red blood cell. See *Blood group markers*.  
 to proliferating cells, in cell cycle analy-  
 sis, 179, 190-192
- Antiglobulin test, in antibody screening,  
 690-692  
 in crossmatching, 692-694
- Antimitochondrial antibodies, in chronic  
 active hepatitis, 33  
 in primary biliary cirrhosis, 35-36
- Antineutrophil cytoplasmic  
 autoantibodies, 85-98  
 C-pattern, 85-87  
 Wegener's granulomatosis and, 87, 89  
 circulating, 92, 94  
 conditions associated with, 92  
 detection of, 86-87  
 elastase type, 91-92  
 historical aspects of, 85-86  
 in primary sclerosing cholangitis, 37-38  
 in Wegener's granulomatosis, 87, 89  
 lactoferrin type, 91-92  
 myeloperoxidase recognition by, 85-87,  
 89-91, 94
- P (perinuclear/nuclear staining)-pattern,  
 86, 92  
 pathogenicity of, 92, 94  
 sensitivity of, 91  
 specificity of, 91
- Antinuclear antibodies, detection methods  
 for, 15-16  
 in chronic active hepatitis, 26, 29  
 in recurrent spontaneous miscarriage,  
 407  
 in rheumatic disease, 2  
 tests for, 7
- Antiphospholipid antibodies, animal  
 models for, 48

- avidity of, 49  
 binding to phospholipids, 49-50  
 characteristics of, 48-51  
 cofactors for, 50-51  
 familial associations of, 43  
 in neurologic disease, 75-76  
 in recurrent spontaneous miscarriage, 407  
 incidence of, 42-43  
 isotypes of, 49  
 pathogenicity of, 51-52  
 specificity of, 49-50
- Antiphospholipid antibody syndrome, 41-60**  
 historical background of, 41-42  
 primary, clinical manifestations of, 43-46  
 treatment of, 46-48
- Antiribosomal P protein, antibodies to, lupus psychosis and, 76**
- Antisperm antibodies, detection of, 399-400, 402**
- Antithrombin III, transfusion of, 751-753**
- Antiviral drug treatment, of transfusion components, 793-794**
- Apheresis, components from, uses of, 774-775**  
 donor screening for, 681  
 platelets from, 663, 774-775  
 techniques for, 774-775
- Aplastic anemia, diagnosis of, molecular probe techniques in, 115**
- Aprotinin, in hemostasis, 776-777**
- Artificial insemination, ethical and legal considerations in, 430-436**
- Autoantibodies. See also specific antibody, e.g., Antinuclear antibodies.**  
 in chronic active hepatitis, 26-27, 29-33  
 in CREST syndrome, 12-13  
 in Eaton-Lambert syndrome, 77-78  
 in neurologic disease, 61-83  
 to antiribosomal P protein, 76  
 to calcium channel, 77-78  
 to Ki antigen, 77  
 to neurofilament, 77  
 to neuronal ganglioside antigens, 64-75  
 to neuronal proteins, 62-64  
 to phospholipids, 75-76  
 in primary biliary cirrhosis, 35-36  
 in primary sclerosing cholangitis, 37-38  
 in rheumatic disease, 1-23  
 biological functions of, 18-19  
 dermatomyositis, 11-12  
 detection methods for, 15-16  
 drug-induced lupus erythematosus, 8-9  
 mixed connective tissue disease, 9-10  
 of rare occurrence, 16-17  
 polymyositis, 11-12  
 rheumatoid arthritis, 13-15  
 scleroderma, 12-13  
 Sjögren's syndrome, 10-11  
 systemic lupus erythematosus, 2-8, 76, 90  
 to Me autoantigen, 17-18  
 to nuclear lamins, 16-17  
 to poly (ADP-ribose) polymerase, 17  
 in Wegener's granulomatosis, 87, 89  
 to neutrophils, 91-92
- Autoimmune disease, antiphospholipid antibody syndrome, 41-60**  
 of liver, 25-40  
 chronic active hepatitis, 26-34  
 primary biliary cirrhosis, 34-37  
 primary sclerosing cholangitis, 37-38
- Autoimmune disorders, in blood donors, guidelines for, 678**
- Autoimmune thrombocytopenia, platelet transfusion in, 660-661**
- Autologous transfusion. See under Transfusion.**
- Automated reagin test, for syphilis, 529**
- Automation, in laboratory testing, 851-852**
- Autoradiography, in cell cycle analysis, 172-173**
- Avitene, in hemostasis, 777**
- Azathioprine, in chronic active hepatitis, 34**
- B-cell lymphoproliferative disorders, after bone marrow transplantation, detection of, 123-124**
- B-cell prolymphocytic leukemia, flow cytometric analysis in, 260**
- Babesia, in blood transfusion components, donor screening for, 676**  
 inactivation of, 788
- Bacteria, in blood transfusion components, inactivation of. See Microbial inactivation.**  
 testing for, 763
- Bak antigens, in neonatal alloimmune thrombocytopenia, 581**
- Basal body temperature, in ovulation documentation, 393-395**
- Bayes theorem, in paternity inclusion calculation, 629**
- Beckwith-Wiedemann syndrome, prenatal diagnosis of, 499**
- Benzoporphyrin derivative treatment, of transfusion components, 797**
- Bernard-Soulier syndrome, neonatal alloimmune thrombocytopenia and, 581**

- Beta-hexosaminidase A deficiency, in Tay-Sachs disease, 465, 467-470
- Beta-propiolactone treatment, of transfusion components, 795
- Biliary cirrhosis, primary, 34-37
- Bilirubin, in amniotic fluid, in hemolytic disease of newborn, 559-561
- Biohazardous waste disposal, regulations on, 841
- Blastomycosis, prenatal diagnosis of, 544-545
- Blood, fetal, disorders of, diagnosis of, 512-517  
sampling of, 495. *See also Cordocentesis.*  
lysis of, for flow cytometry, 266-268  
shipment of, regulations on, 841  
storage of, before transfusion, 706  
transfusion of. *See Transfusion.*
- Blood banks, liability of. *See Legal issues, in transfusion medicine.*  
regulation of. *See Regulatory and legislative issues, in transfusion medicine.*
- Blood-borne Pathogen Standard, 840-841
- Blood components, transfusion of. *See Transfusion.*
- Blood donors, safety for, 678-680  
screening of, 669-683  
confidential unit exclusion and, 673-675, 703  
donor education in, 670-671  
for apheresis, 681  
for donor safety, 678-680  
for infectious diseases, 675-676, 701-703  
for red cell antibodies, 687-688  
goals of, 669  
in autologous donation, 680  
in directed donation, 681  
medical history in, 672-673, 677-678  
medication use and, 677  
national donor referral registry and, 681-682  
vaccination and, 676-677
- Blood group markers, hemolytic disease of newborn and, 556-559  
in linkage analysis, 454-455  
in parentage analysis, 621-625
- Blood protein polymorphisms, in parentage analysis, 625-627
- Blood shield statutes, 820-821
- Bone marrow transplantation, graft-versus-host disease in, 749-751  
minimal residual disease detection in, 129-150, 764-765  
acute lymphoblastic leukemia, 139-143  
acute myelogenous leukemia, 145  
chronic myelogenous leukemia, 133-139  
hybridization assay in, 130-131, 137  
immunoglobulin rearrangements, 144  
immunophenotyping in, 130  
in autologous marrow, 115-116, 146  
lymphoma, 146  
polymerase chain reaction in, 131-133, 135-145  
Southern blot in, 130, 135  
T-cell receptor rearrangements, 144-145  
molecular probe techniques in, 113-128  
for engraftment documentation, 119-121  
for hemopoietic reconstitution clonality determination, 121-122  
for histocompatibility typing, 116-119  
for immunodeficiency evaluation, 122  
for infection diagnosis, 122-123  
for pretransplant disease identification, 114-116  
for secondary malignancies detection, 123-124  
minisatellite type, 120
- Borreliosis, prenatal diagnosis of, 524-525
- Bovine cervical mucus penetration test, 403
- Br antigens, in neonatal alloimmune thrombocytopenia, 581
- Breast cancer, paraneoplastic syndrome in, autoantibodies in, 63-64
- Bromodeoxyuridine incorporation method, in cell cycle analysis, 179, 190
- Calcium channels, antibodies to, in neurologic disease, 77-78
- Canadian Association of Pathologists, workload recording method of, 339-341
- Cancer, cell proliferation markers in. *See Cell proliferation markers.*  
immunotherapy in, monoclonal antibodies in. *See under Monoclonal antibodies.*  
in blood donors, guidelines for, 677-678  
integrins role in, 220-222  
paraneoplastic syndromes in, autoantibodies in, 62-64, 77-78  
recurrence of, from transfusion immunosuppression, 717, 724-726  
secondary, in bone marrow transplantation, detection of, 123-124
- Candidiasis, prenatal diagnosis of, 544
- Capacitation, of sperm, 413-414

- Carcinogenesis, cell proliferation markers and, 164-168
- Carcinoma, in blood donors, guidelines for, 678
- Cardiac disease, in antiphospholipid antibody syndrome, 46
- cDNA sequencing, in granulomatous disease, 297
- Cell(s), adhesion of, integrins in. See *Integrins*.
- differentiation of, integrins in, 222-223
- fixation of, for flow cytometry, 273
- labeling of, for flow cytometry, 269-273
- signal transduction pathways of, integrin interaction with, 224-226
- Cell counters, in fetal lung maturity assessment, 615-617
- Cell cycle, cell proliferation markers and, 169-180
- phases of, 169-171
- quantitative measurement of, 171-180
- Cell proliferation antigens. See *Proliferating cell antigens*.
- Cell proliferation markers, 163-199
- carcinogenesis and, 164-168
- cell cycle and, 169-180
- clinical significance of, 180-192
- growth kinetics and, 168-169
- measurement of, antigen analysis in, 190-192
- flow cytometry in, 186-190
- halogenated pyrimidine incorporation in, 190
- nuclear organizer region technique in, 192
- metastasis and, 166-168, 182-184
- prognostic implications of, 180-182, 186-190
- therapeutic implications of, 184-186
- tumor biology and, 164-169
- tumor heterogeneity and, 168
- Centromere antigens, antibodies to, in scleroderma, 13
- Cerebellar degeneration, paraneoplastic, autoantibodies in, 62-63
- Cerebrospinal fluid testing, in coccidioidomycosis, 545
- Cervical mucus penetration test, 403
- Chagas' disease, transmission of, in transfusion, 763
- blood donor screening for, 676
- Chemical inactivation, of pathogens, in transfusion components, 793
- Chemiluminescence assay, monocyte-mediated, in hemolytic disease of newborn, 562
- Chemotherapy, cell proliferation markers in, 184-186
- monoclonal antibody-drug conjugates (chemoimmunoconjugates) in, 207-210
- Chicken pox, prenatal diagnosis of, 511
- Chimerism, in bone marrow transplantation, 119-121
- Chlamydial infections, diagnosis of, in infertility evaluation, 398-399, 402
- in recurrent spontaneous miscarriage, 405
- prenatal, 538
- Cholangitis, primary sclerosing, 37-38
- Chorionic villus sampling, 494
- efficacy of, 500
- in granulomatous disease detection, 298
- in hemolytic disease of newborn, 564
- Chromatography, high-pressure liquid, for neopterin, 102-103
- thin-layer, in antiganglioside antibody detection, 74
- in fetal lung maturity assessment, 609-611
- Chromosomal analysis, in recurrent spontaneous miscarriage, 406
- prenatal, 497-499
- cordocentesis in, 505-507
- Chromosome jumping, in linkage analysis, 455
- Chromosome walking, in linkage analysis, 455
- Chronic inflammatory demyelinating polyneuropathy, plasmapheresis in, 600
- Chronic lymphocytic leukemia, flow cytometric analysis in, 258, 260
- Chronic myelogenous leukemia, minimal residual cells from, detection of, 133-139
- Cirrhosis, primary biliary, 34-37
- Clinical Laboratory Improvement Amendments of 1988, 839-840, 850-851
- Clonal deletion theory, of immunosuppression, in transfusion, 730
- Clonality, in bone marrow transplantation, molecular probe determination of, 121-122
- Clustering, in test selection, 363-370
- Coagulopathy, antithrombin III replacement in, 751-753
- cryoprecipitate transfusion in, 665, 772
- diagnosis of, 764-765
- dilutional, plasma transfusion in, 663-664
- in massive transfusion, 745, 748
- plasma transfusion in, 664, 772-773
- prenatal diagnosis of, 512-513
- preoperative evaluation of, transfusion therapy and, 773-774

- Coccidioidomycosis, prenatal diagnosis of, 545-546
- Collagen, microfibrillar, in hemostasis, 777
- College of American Pathologists, proficiency testing programs of, 850-851
- workload recording method of. See *Workload recording method.*
- Combined immunodeficiency, prenatal diagnosis of, 513-514
- Compatibility testing, in transfusion. See *Red cells, transfusion of, safety in.*
- Complement fixation test, in coccidioidomycosis, 545
- in toxoplasmosis, 541-542
- in trypanosomiasis, 543
- Confidential unit exclusion, in blood donation, 673-675, 703
- Congenital disease. See also *Genetic disease.*
- markers for, alpha-fetoprotein as, 481-492
- prenatal diagnosis of, cordocentesis in. See *Cordocentesis.*
- Congenital varicella syndrome, 536
- Connective tissue disease, mixed, autoantibodies in, 9-10
- Cordocentesis, 503-522
- complications of, 504-505
- diagnostic uses of, acid-base balance evaluation, 517-518
- chromosomal analysis, 505-507
- congenital infection identification, 507-512
- hematologic disorders, 512-517
- hemolytic disease of newborn, 563-564
- metabolic status assessment, 517-518
- historical review of, 503
- methodology for, 503-504
- Corticosteroids, in chronic active hepatitis, 34
- Counseling, linkage analysis and, 458-460
- Coupling, in linkage analysis, 450
- Coxsackievirus infections, prenatal diagnosis of, 536
- CREST syndrome, autoantibodies in, 12-13
- Creutzfeldt-Jakob disease, screening for, in blood donors, 676
- Crohn's disease, transfusion in, immunosuppression in, 727-728
- Crossmatching, in transfusion, 692-694
- Cryoprecipitate, transfusion of, 665
- guidelines for, 772
- Cryopreservation, for flow cytometry, 268-269
- of embryo, in assisted reproduction, 421, 430-431
- Cryptococcosis, prenatal diagnosis of, 546
- Culture, of *Blastomyces dermatitidis*, 544-545
- of *Borrelia burgdorferi*, 524
- of chlamydia, 538
- of embryos, for in vitro fertilization, 421-424
- of enteroviruses, 536
- of herpes simplex virus, 535
- of HIV, 318-319, 533
- of *Listeria monocytogenes*, 526
- of microorganisms, in infertility evaluation, 398-399
- of *Mycobacterium tuberculosis*, 527
- of *Mycoplasma hominis*, 529
- of *Neisseria gonorrhoeae*, 528
- of rubella virus, 534
- of streptococci, 525-526
- of *Ureaplasma urealyticum*, 529
- of varicella-zoster virus, 536-537
- Cystic fibrosis, linkage analysis in, 458-459
- Cytapheresis, in pregnancy, 593-594
- Cytochrome P-450 antibodies, in chronic active hepatitis, 30-32
- Cytogenetics, prenatal, 496
- cordocentesis in, 505-507
- efficacy of, 500-501
- fetal cells in maternal blood, 496
- in chromosomal abnormality detection, 497-500
- indications for, 496-497
- sample collection for, 494-495
- Cytomegalovirus infection, prenatal diagnosis of, 510, 531-532
- transmission in transfusion, reduction of, 713-714, 763
- to neonates, 747
- viral inactivation and, 788
- Cytophilic antibody, in flow cytometry, of lymphocyte markers, 262
- Cytosolic components, autoantibodies against, in chronic active hepatitis, 32-33
- D antigens, determination of, for transfusion, 686-687, 689
- Danazol, in hemostasis, 776
- Data collection, for test selection, 356
- in workload recording method, 344-345
- Data organization, for test selection. See *Test selection.*
- DDAVP (desmopressin), in hemostasis, 775

- 3-Deamino-3-(4-morpholinyl)-doxorubicin-monoclonal antibody conjugate, in cancer immunotherapy, 208-209
- 1-Deamino-8D-arginine (DDAVP), in hemostasis, 775
- Decision making, for test selection. See *Test selection*.
- Dehydroepiandrosterone sulfate, assessment of, in infertility evaluation, 398
- Dendrograms, in test selection, 361
- Dermatomyositis, autoantibodies in, 11-12
- 4-Desacetylvinblastine-3-carboxyhydrazide-monoclonal antibody conjugate, in cancer immunotherapy, 209-210
- Desmopressin, in hemostasis, 775
- Detergent treatment, of transfusion components, 798
- Diabetes mellitus, alpha-fetoprotein results and, 487
- DiGeorge syndrome, prenatal diagnosis of, 456, 498
- Direct antiglobulin test, in hemolytic disease of newborn, 556
- Direct sequencing, of DNA, in parentage analysis, 634
- Directed donation, of blood, transfusion of, 681, 780
- Disintegrins, 230
- DNA, denatured, antibodies to, in drug-induced lupus erythematosus, 8-9
- halogenated pyrimidine incorporation into, in cell cycle analysis, 179
- identification of, in HIV, 319-320
- native, antibodies to, in SLE, 2-3
- nucleolar organizer regions of, in cell proliferation measurement, 179-180, 192
- quantitation in cell cycle analysis, 173-180
- clinical significance of, 180-192
- DNA hybridization, in bone marrow minimal residual disease, 130-131, 137
- in HIV testing, 319-320
- DNA index, in cell cycle analysis, 174-176
- DNA ploidy. See *Ploidy*.
- DNA probes, in malaria diagnosis, 542
- DNA-specific dyes, in cell cycle analysis, 173-179
- DNA studies, in parentage analysis, 630-636
- DNA topoisomerase II, antibodies to, in rheumatic disease, 17-18
- Donors, blood. See *Blood donors*.
- Doppler analysis, in hemolytic disease of newborn, 563
- Down syndrome, markers for, 489-490
- Drug(s), alpha-fetoprotein results and, 487-488
- exclusion of, from donated blood, 677
- lupus erythematosus induced by, antibodies in, 8-9
- monoclonal antibody-drug conjugates with, 207-210
- Duffy antigens, in hemolytic disease of newborn, 557
- in parentage analysis, 623
- Dyes, DNA-specific, in cell cycle analysis, 173-179
- Early antigen of Epstein-Barr virus, antibodies to, in rheumatoid arthritis, 14
- Eaton-Lambert syndrome, autoantibodies in, 77-78
- Effector cells, in immunotherapy, activation of, 202-205
- redirection to tumor sites, 205-207
- Elastase, antineutrophil cytoplasmic autoantibodies to, 91-92
- Electrolytes, in embryo culture media, 423
- Electron microscopy, pseudoreplica method of, in cytomegalovirus detection, 531
- Electrophoresis, in hexosaminidase A detection, 468
- in parentage analysis, 625-627
- ELISA. See *Enzyme-linked immunosorbent assay*.
- Embryo, development of, integrins in, 222-223
- for assisted reproduction, cryopreservation of, 430-431
- culture of, 421-424
- ethical and legal status of, 441-445
- handling of, 415-421
- Encephalomyelitis, paraneoplastic, autoantibodies in, 64
- Endometrial biopsy, in infertility evaluation, 396-397
- in recurrent spontaneous miscarriage, 406-407
- Endometrial carcinoma stage I prognostic index, 189
- Endothelial cells, antibodies to, 51-52
- integrins associated with, 219
- Enterovirus infections, prenatal diagnosis of, 535-536
- Environmental Protection Agency, medical waste regulation by, 841



- Enzyme analysis, in phosphatidylglycerol determination, 611  
 in Tay-Sachs disease diagnosis, 469
- Enzyme immunoassay, for alpha-fetoprotein, 484-485  
 for luteinizing hormone surge assessment, 395  
 in autoantibody detection, 15-16  
 in chlamydial infections, 538  
 in cryptococcosis, 546  
 in gonorrhea, 528  
 in hepatitis B, 538  
 in HIV infection, 532  
 in streptococcal infections, 526
- Enzyme-linked immunosorbent assay, for hormones, in infertility evaluation, 397  
 for infectious organisms, *Borrelia burgdorferi*, 524  
 in infertility evaluation, 397  
*Listeria monocytogenes*, 526  
*Toxoplasma gondii*, 508, 540-541  
*Treponema pallidum*, 530  
 in antiganglioside antibody detection, 73-74  
 in antineutrophil cytoplasmic autoantibody detection, 86-87  
 in autoantibody detection, 15-16  
 in HIV testing, 311-314, 317-318  
 in interleukin-2 soluble receptor analysis, 104
- Epidermal growth factor receptors, in tumor, monoclonal antibodies directed to, 210-211
- Epithelial cells, integrins associated with, 218-220
- Epstein-Barr virus, detection of, after bone marrow transplantation, 123  
 in blood transfusion components, 763  
 rheumatoid arthritis and, 14  
 transmission in transfusion, reduction of, 714-715
- Error reports, in transfusion medicine, 837
- Erythema infectiosum (parvovirus B19 infection), in blood transfusion components, testing for, 763  
 prenatal diagnosis of, 511-512, 537
- Erythrocytes. See Red cells.
- Erythroderma, postoperative, in graft-versus-host disease, 749
- Erythropoietin, as transfusion alternative, 658, 777-778  
 in hemolytic disease of newborn, 564-565
- Estradiol, assessment of, in infertility evaluation, 398
- Estril, unconjugated, in Down syndrome screening, 489-490
- Estrogens, in hemostasis, 776
- Ethical and legal considerations, in assisted reproduction, 429-448  
 exploitation and, 439-442  
 extrauterine embryo status, 442-445  
 nuclear family fate and, 432-439  
 in Tay-Sachs screening, 476-477
- Ethidium bromide, in cell cycle analysis, 174
- Exclusion filtration, of transfusion components, for microbial removal, 791
- Factor VIII, transfusion of, 665
- Family law, in assisted reproduction. See under *Ethical and legal considerations*.
- FDA (Food and Drug Administration), transfusion medicine regulation by, 836-838
- Fertilization, in vitro. See *In vitro fertilization*.
- Fetus, alloimmune thrombocytopenia development in, 577-586  
 alpha-fetoprotein levels in. See *Alpha-fetoprotein*.  
 cells of, in maternal blood, 496  
 diagnosis of disorders in, blastomycosis, 544-545  
 blood disorders, 512-517. See also *Hemolytic disease of newborn*.  
 blood sampling for, 495. See also *Cordocentesis*.  
 candidiasis, 544  
 chlamydial infection, 538  
 coccidioidomycosis, 545-546  
 cryptococcosis, 546  
 cytomegalovirus infection, 510, 531-532  
 enterovirus infections, 535-536  
 gonorrhea, 527-528  
 hepatitis B, 537-538  
 herpes simplex virus infection, 534-535  
 HIV infection, 532-533  
 hydrops, 516-517  
 infections, 523-552  
 listeriosis, 526-527  
 Lyme disease, 524-525  
 malaria, 542  
 mycoplasmal infections, 528-529  
 papillomavirus infection, 538-539  
 parvovirus B19 infection, 511-512, 537  
 rubella, 510-511, 533-534  
 streptococcal infections, 525-526  
 syphilis, 529-530  
 Tay-Sachs disease, 468-469  
 toxoplasmosis, 507-510, 539-542



- trypanosomiasis, 543  
 tuberculosis, 527  
 varicella-zoster virus infection, 511, 536-537  
 lung maturity assessment in, 603-630  
 parentage analysis of, 636  
 transfusion for, in alloimmune thrombocytopenia, 584  
 in hemolytic disease of newborn, 566-568
- Feulgen staining technique, in static cytophotometry, 178
- Fibrillarin, antibodies to, in scleroderma, 13
- Fibrin surgical adhesive, in hemostasis, 777
- Fibrinogen, integrin recognition of, 226-227, 229  
 transfusion of, 665
- Fibronectin, integrin recognition of, 226-227
- Ficoll-Hypaque technique, 268
- Fifth disease (parvovirus B19 infection), in  
 blood transfusion components, 763  
 prenatal diagnosis of, 511-512, 537
- Filtration, of transfusion components, for  
 microbial removal, 791-792
- Flow cytometry, in cell cycle analysis, 174-177, 186-190  
 in HIV testing, 318  
 in lymphocyte marker analysis, 237-275  
 antibody labeling techniques in, 263-266  
 biohazards precautions in, 274  
 cell fixation for, 273  
 cell gating settings for, 243-244  
 cell labeling for, 269-273  
 compensation settings for, 241, 243  
 computer data acquisition in, 239  
 fluorochromes for, 245-246, 271-273  
 in B-cell prolymphocytic leukemia, 260  
 in chronic lymphocytic leukemia, 258, 260  
 in follicular center cell lymphoma, 260  
 in hairy cell leukemia, 260  
 in plasmacytoid lymphocytic lymphoma, 260  
 in T-cell chronic lymphoproliferative disease, 260, 262  
 instrumentation for, 238-245  
 monoclonal antibodies for, 246-247  
 procedure for, 263-274  
 quality control in, 244-245, 273-274  
 results interpretation in, 247, 255-263  
 settings in, 239-244  
 specimen handling in, 266-269  
 technical problems in, 262-263  
 voltage gain settings for, 239-241  
 in proliferating-cell antigen analysis, 190-192
- Fluorescein, in flow cytometry, 245, 263-264
- Fluorescence, depolarization of, in fetal lung maturity assessment, 615-616
- Fluorescent treponemal antibody absorption test, for syphilis, 529-530
- Fluorochromes, in cell cycle analysis, 173-179  
 in flow cytometry, of lymphocyte markers, 245-246, 271-273
- Foam-stability assay, in fetal lung maturity assessment, 614-615
- Follicle-stimulating hormone, assessment of, in infertility evaluation, 398, 402
- Follicular center cell lymphoma, flow cytometric analysis in, 260
- Food and Drug Administration, transfusion medicine regulation by, 836-838
- Fragile X syndrome, prenatal diagnosis of, 499
- Fungal infections. See specific infection.
- Fy antigens, in hemolytic disease of newborn, 557
- Gamete intrafallopian transfer, ethical and legal considerations in, 430-432
- Gamma globulin, in neonatal alloimmune thrombocytopenia, 584-585  
 in plasmapheresis, 599
- Gamma irradiation, of transfusion components, for microbial inactivation, 794-795  
 in graft-versus-host disease prevention, 750-751
- Gangliosides, 64-75  
 antibodies to, detection of, 72-75  
 diseases associated with, 70  
 mechanism of action of, 72  
 origin of, 71-72  
 pathogenicity of, 71  
 specificity of, 70-71  
 characteristics of, 70  
 molecular structure of, 65  
 tissue localization of, 65, 70
- Gene-dosage methods, in linkage analysis, 455-456
- Gene mapping. See under *Linkage analysis*.
- Genetic disease. See also *Congenital disease*.  
 diagnosis of, 493-502  
 alpha-fetoprotein markers in, 481-492  
 chromosomal syndromes, 497-499  
 efficacy of methods for, 500-501  
 genomic imprinting and, 499-500

- Genetic disease (*Continued*)  
 in assisted reproductive technology, 495  
 indications for, 496-497  
 overview of, 493-494  
 preconceptive, 495-496  
 techniques for, 494-495, 500-501  
 with fetal cells in maternal blood, 496  
 prediction of, linkage analysis in, 449-462  
   counseling in, 458-460  
   definitions in, 450  
   gene mapping methods in, 450-458  
   Human Genome Initiative project, 460  
   Tay-Sachs disease, 463-480  
   recurrent spontaneous miscarriage and, 406  
 Gestational age, alpha-fetoprotein results and, 486  
 GIFT (gamete intrafallopian transfer), ethical and legal considerations in, 430-432  
 Glioblastoma multiforme, integrins in, 220-221  
 Glioma, immunotherapy in, monoclonal antibodies in, 209-210  
 Glucose, in embryo culture media, 423  
 Glucose-6-phosphate dehydrogenase deficiency, defective respiratory burst in, 284-285  
 Glue, fibrin, in hemostasis, 777  
 Glutathione reductase deficiency, defective respiratory burst in, 285  
 GM<sub>2</sub> ganglioside, in Tay-Sachs disease, 466-467  
 Gonorrhea, prenatal diagnosis of, 527-528  
 Goodpasture's syndrome, plasmapheresis in, 600  
 Graft-versus-host disease, in transfusion, 718, 749-751  
 Granulocyte-macrophage colony-stimulating factor, in cancer immunotherapy, 205  
 Granulocyte-monocyte colony stimulation factor, as transfusion alternative, 778  
 Granulomatous disease, 277-305  
   autoantibodies in, 87, 89  
   carrier state of, diagnosis of, 292-293  
   classification of, 280-281, 284, 292, 294  
   clinical features of, 289, 292-293  
   incidence of, 280  
   infections in, 288-289, 292  
   pathogenesis of, 280-288  
   phagocyte respiratory burst and, defective, 280-288  
   normal, 277-280  
   regulation of, 279-280  
   prenatal diagnosis of, 513-514  
   testing in, cDNA sequencing, 297  
   NADPH oxidase component gene characterization, 293, 295  
   Northern analysis, 296  
   polymerase chain reaction, 297  
   pre-atal, 297-299  
   Southern analysis, 296  
 Growth factors, hematopoietic, as transfusion alternatives, 777-778  
   receptors for, in tumor, monoclonal antibodies directed to, 210-211  
 Guillain-Barré syndrome, in blood donors, guidelines for, 678  
   plasmapheresis in, 599-600  
 Hairy cell leukemia, flow cytometric analysis in, 260  
 Halogenated pyrimidine incorporation method, in cell cycle analysis, 179, 190  
 Hamster test (sperm penetration assay), 402-403  
 Hazardous waste disposal, regulations on, 841  
 Health Care Financing Administration, transfusion medicine regulation by, 838-840  
 Heart, transplantation of, rejection markers in, 106, 108-109  
 Heat shock protein 90, antibodies to, in rheumatic disease, 6  
 Heat treatment, of transfusion components, for microbial inactivation, 791  
 Hemagglutination test, in syphilis, 529-530  
   in toxoplasmosis, 541  
 Hemapheresis. *See also Plasmapheresis.*  
   in pregnancy, 587-602  
   in dermatologic disease, 601  
   in gastrointestinal disease, 601  
   in hematologic disease, 593-598  
   in neurologic disorders, 599-600  
   in renal disease, 600  
   in rheumatologic disease, 600  
   indications for, 587  
   machine (centrifugal), 588  
   manual, 588  
   nontreatment, 592-593  
   replacement solutions for, 598-599  
   technique for, 592  
   technology for, 587-588  
   therapeutic, 593-601  
   volume calculations for, 588-592  
 Hematocrit, extremely low, death in, 656  
 Hematologic disorders. *See under Blood.*

- Hematology, polymerase chain reaction tests in, 764-765
- Hematopoietic growth factors, as transfusion alternatives, 777-778
- Hematorporphyrin derivative treatment, of transfusion components, 796-797
- Hemizona assay, in infertility evaluation, 403-404
- Hemoglobin, level of, as transfusion trigger, 656-658
- Hemoglobinopathy, diagnosis of, 764  
prenatal diagnosis of, 513  
transfusion in, immunosuppression in, 727
- Hemolysis, in transfusion reaction, 694-696
- Hemolytic anemia, in antiphospholipid antibody syndrome, 45
- Hemolytic disease of newborn, 553-576  
causes of alloimmunization in, 554-555  
historical review of, 553-556  
immunoglobulin therapy in, 569  
intrauterine intravascular transfusion in, 566-568  
pathophysiology of, 564-566  
plasmapheresis in, 568-569, 596-598  
prenatal diagnosis of, 516-517  
prenatal monitoring in, invasive methods, 563-564  
noninvasive methods, 561-563  
traditional methods, 559-561  
preterm labor induction in, 566  
prevention of, current methods for, 556-559  
in 1980s, 554-556  
promethazine hydrochloride therapy in, 568  
treatment of, 566-570
- Hemolytic uremic syndrome, plasmapheresis in, 594-596
- Hemophilia, prenatal diagnosis of, 512-513  
transfusion in, immunosuppression in, 727  
of cryoprecipitate, 665
- Hemostasis, defects of, platelet transfusion in, 659-663  
preoperative evaluation of, transfusion therapy and, 773-774  
techniques for, as transfusion alternatives, 775-777
- Hepatitis, autoimmune chronic active, 26-34  
classification of, 26-27  
clinical features of, 27-28  
diagnosis of, 26-27  
etiology of, 29-33  
immunogenetics of, 33-34  
pathogenesis of, 29-33  
pathology of, 27-28  
treatment of, 34
- Hepatitis B virus, in blood transfusion components, donor screening for, 675, 701-702, 704-705  
inactivation of. *See Microbial inactivation.*  
testing for, 763  
prenatal detection of, 537-538
- Hepatitis C virus, in blood transfusion components, donor screening for, 675, 704  
inactivation of, 788-789  
testing for, 762
- Herpes simplex virus infection, prenatal diagnosis of, 534-535
- Herpes viruses, in blood transfusion components, testing for, 763
- Heteroduplex formation, in Tay-Sachs disease assessment, 474
- Hexosaminidase A deficiency, in Tay-Sachs disease, 465, 467-470
- Histidyl tRNA synthetase, antibodies to, in polymyositis, 11
- Histocompatibility testing, in bone marrow transplantation, 116-119
- Histones, antibodies to, in drug-induced lupus erythematosus, 8-9
- HIV. *See Human immunodeficiency virus.*
- HLA. *See Human leukocyte antigens.*
- Homologous blood, limited exposure to. *See under Transfusion.*
- Hormones, assessment of, in infertility evaluation, 397-398, 402
- Human chorionic gonadotropin assay, in Down syndrome, 490  
in recurrent spontaneous miscarriage, 408
- Human Genome Initiative project, 460
- Human herpes virus 6, in blood transfusion components, testing for, 763
- Human immunodeficiency virus, genetics of, 308  
in blood donors, screening for. *See Blood donors, screening of.*  
in blood transfusion components, inactivation of. *See Microbial inactivation.*  
testing for, 762, 836  
testing for, 307-335  
antibody-dependent cellular cytotoxicity and, 317  
antibody detection methods, 310-317  
antigen detection assays, 317-318  
direct detection methods, 317-320  
enzyme-linked immunosorbent assay, 311-314  
hybridization techniques, 320

- Human immunodeficiency virus (*Continued*)
- in infants, 322-324
  - in transfusion medicine, 762
    - FDA role in, 836
  - indirect immunofluorescence anti-body assay, 316
  - peptide immunoassays, 313-314
  - polymerase chain reaction, 319-320
  - prenatal, 323-324
  - radioimmunoprecipitation antibody assay, 316-317
  - rapid agglutination screening assays, 314
  - RNA detection, 319-320
  - serologic stages and, 308, 310
  - type 1 vs. type 2, 314
  - viral culture methods, 318-319
  - viral DNA/RNA detection methods, 319-320
  - virus characteristics and, 307-308
  - Western blot test, 314-316
  - transmission of, in transfusion, 728-729
    - legal issues in. See Legal issues, in transfusion medicine.
    - prevention of, 701-710
    - reduction of, with leukocyte-reduced preparations, 714-715
- Human immunodeficiency virus infection,
- incidence of, in blood donors, 669
  - prenatal diagnosis of, 532-533
  - transmission of, prevention of, in transfusion, 701-710
- Human leukocyte antigens, antibodies to,
- in blood transfusion, 724
  - in parentage analysis, 627-628, 633
  - reduction of, in transfusion components, 711-713
  - sharing of, in recurrent spontaneous miscarriage, 407-408
  - typing of, 763-764
- Human papillomavirus infections,
- prenatal diagnosis of, 538-539
- Human T-lymphotropic virus-I, in blood transfusion components,
- inactivation of, 788-789, 792
  - reduction of, leukodepletion in, 714-715
  - testing for, 762
- Hybridization techniques, in bone marrow minimal residual disease, 137
- in HIV testing, 319-320
- Hydralazine, antineutrophil cytoplasmic autoantibodies induced by, 92
- lupus erythematosus induced by, 8-9
- Hydrogen peroxide, sperm damage by, 414-415
- Hydrops fetalis. See also *Hemolytic disease of newborn.*
- diagnosis of, 516-517
- 17-Hydroxyprogesterone, assessment of,
- in infertility evaluation, 398
- Hypergammaglobulinemia, in chronic active hepatitis, 26-27
- in primary biliary cirrhosis, 35
- Hypo-osmotic swelling test, of sperm, 403, 414
- Hypothermia, in massive transfusion, 745
- Hypoxanthine phosphoribosyltransferase, in embryo culture media, 423
- Hypoxemia, fetal, diagnosis of, 518
- Hysterosalpingography, in infertility evaluation, 397
- in recurrent spontaneous miscarriage, 406
- Hysteroscopy, in infertility evaluation, 397
- Image analysis, in cell cycle analysis, 186-190
- in DNA content analysis, 177-180
- Immediate spin crossmatch, in transfusion, 692-694
- Immune tolerance, in transfusion, 731
- Immunobead binding test, for antisperm antibodies, 400, 402
- Immunodeficiency. See *Immunosuppression.*
- Immunodiffusion test, in autoantibody detection, 15
- in coccidioidomycosis, 545
- Immunofluorescence assay. See also *Indirect immunofluorescence assay.*
- in chlamydial infection, 538
  - in herpes simplex virus infection, 535
  - in HIV infection, 316, 532
  - in toxoplasmosis, 508
  - in varicella-zoster virus infection, 536-537
- Immunoglobulin(s), allotyping of, in parentage analysis, 625
- high-dose therapy with, in hemolytic disease of newborn, 570
- rearrangement of, in leukemia, 144
- Immunoglobulin G, assay for, in toxoplasmosis, 540
- subclasses of, in hemolytic disease of newborn, 556-557
- Immunoglobulin M assay, in cytomegalovirus detection, 532
- in parvovirus B19 infection, 537
  - in rubella, 534
  - in toxoplasmosis, 540
- Immunology, anti-neutrophil cytoplasmic autoantibodies in, 85-98
- cell proliferation markers in, 163-199
  - in allograft rejection prediction, 99-111

- in antiphospholipid antibody syndrome, 41-60
- in cancer immunotherapy, 201-216
- in granulomatous disease, 277-305
- in HIV testing, 307-335
- in liver autoimmune disease, 25-40
- in marrow transplantation, 113-128
  - residual disease diagnosis in, 129-151
- in neurologic disease, 61-83
- in rheumatic disease, autoantibodies to intracellular antigens in, 1-23
- integrin-mediated cell adhesion, 217-236
- lymphocyte markers in, 237-275
- Immunophenotyping, in bone marrow
  - minimal residual disease, 130
- Immunosuppression, in blood
  - transfusion, 723-741
- cancer recurrence and, 717, 724-726
- chronic, 726-727
- Crohn's disease and, 727-728
- leukocyte-depleted components and, 716-719
- mechanisms of, 729-731
- plasma role in, 728-729
- postoperative infection and, 717, 726
- transplantation and, 723-724
- prenatal diagnosis of, 513-514
- Immunosuppressive therapy, in hemolytic disease of newborn prevention, 554-555
- Immunotherapy, cancer, monoclonal antibodies in. See under *Monoclonal antibodies*.
- Immunotoxins, in cancer, 207-209
- In situ hybridization, in linkage analysis, 456-457
- In vitro fertilization, ethical and legal considerations in, 430-432, 441-445
- preimplantation genetic testing in, 495
- procedure for, 411-428
- culture conditions in, 421-424
- embryo in, 415-421
- oocytes in, 415-421
- sperm in, 411-415
- In vivo crossmatch, in transfusion, 694
- Inborn errors of metabolism, Tay-Sachs disease as model for. See *Tay-Sachs disease*.
- Indirect hemagglutination test, in toxoplasmosis, 541
- Indirect immunofluorescence assay, in
  - antineutrophil cytoplasmic autoantibody detection, 86
  - in antinuclear antibody detection, 15
  - in HIV testing, 316
  - in Lyme disease, 524
  - in malaria, 542
  - in syphilis, 530
  - in toxoplasmosis, 540
  - in trypanosomiasis, 543
- Infants, HIV testing in, 322-324
- newborn, alloimmune thrombocytopenia in, 577-586
- hemolytic disease of. See *Hemolytic disease of newborn*.
- infection diagnosis in. See *Fetus, diagnosis of disorders in*.
- plasma transfusion in, 664-665
- platelet transfusion in, 662-663
- respiratory distress syndrome in, lung maturity in, 603-630
- transfusion in, 746-748
- Infections, congenital, diagnosis of, 507-512
- in bone marrow transplantation, evaluation of, 122-123
- in infertility, 398-399, 402
- in leukocyte adhesion deficiency, 287, 289
- in recurrent spontaneous miscarriage, 405-406
- in transplant patients, indicators of, 105
- postoperative, from transfusion-induced immunosuppression, 717, 726
- prenatal diagnosis of, 523-552
- bacterial, 524-530
- fungal, 543-546
- parasitic, 539-543
- viral, 531-539
- prevention of, in transfusion, 701-710
- Infertility, 393-410
- definition of, 393
- female, antisperm antibody detection in, 399-400
- hormonal assessment in, 397-398
- hysterosalpingography in, 397
- hysteroscopy in, 397
- infection cultures in, 398-399
- laparoscopy in, 397
- luteal phase assessment in, 396-397
- ovulation documentation in, 393-396
- postcoital tests in, 396
- male, evaluation of, 400-404
- Inflammatory bowel disease, in primary sclerosing cholangitis, 37-38
- Information management, for test selection. See *Test selection*.
- Informed consent, for blood donors, 678
- Insemination, artificial, ethical and legal considerations in, 430-436
- Integrins, 217-236
- activation on cell surface, 229-230
- antagonists of, 230-231
- cell type specificity of, 218-220
- in cancer, 220-222
- in cell differentiation, 222-223
- in cell signal mediation, 224-226

Integrins (*Continued*)

- in embryonic development, 222-223
- in melanoma, 221-222
- interaction with actin-cytoskeleton, 223-224
- interaction with ligand, structural basis for, 227-229
- recognition of specific sites in adhesive proteins by, 226-227
- regulation on cell surface, 229-230
- structures of, 217-218

Interleukin(s), in immunosuppression, in transfusion, 730

Interleukin-2 soluble receptor, as transplantation rejection marker, 103-104

- analysis for, 104

Intrahepatic vein, blood sampling from, in fetus, 504-505

Intrauterine transfusion, in alloimmune thrombocytopenia, 584

- in hemolytic disease of newborn, 566-568

Irradiation, of transfusion components, for microbial inactivation, 794-795

- in graft-versus-host disease prevention, 718, 750-751

Isoimmunization. See *Alloimmunization*.

Isojin sperm immobilization assay, 400, 402

Isotretinoin, exclusion of, from donated blood, 677

Jehovah's Witnesses, transfusion

- alternatives for, 778, 780-781

Jo-1 antigen (histidyl tRNA synthetase), antibodies to, in polymyositis, 11

Kala-azar, screening for, in blood donors, 676

Karyotyping, in recurrent spontaneous miscarriage, 406

Kell antigens, in hemolytic disease of newborn, 557

- in parentage analysis, 623

Ki antigen, antibodies to, in neurologic disease, 77

- in rheumatic disease, 5

Ki-67 antigen, quantitation of, 191-192

Kibrick sperm agglutination test, 400, 402

Kidd antigens, in hemolytic disease of newborn, 557

- in parentage analysis, 623

Kidney, transplantation of,

- immunosuppression in, from blood

- transfusion, 716-718, 723-724

- rejection markers in, 104-107

Ko antigens, in neonatal alloimmune thrombocytopenia, 581

Ku antigen, antibodies to, in rheumatic disease, 4-5

Laboratory management, 849-859

- financial planning in, 858

- information system in, 856

- legal complexity of, 850-851

- managerial complexity of, 853-858

- medical complexity of, 852-853

- organization in, 854-856

- team building in, 854-856

- technical complexity of, 851-852

- test selection decisions. See *Test selection*.

- trust building in, 856-858

- workload recording method, 339-352

Laboratory Management Index Program, 349

Lactoferrin, antineutrophil cytoplasmic autoantibodies to, 91-92

Lamellar body distribution, in amniotic fluid, 607, 616-618

Lamins, antibodies to, in rheumatic disease, 16-17

Langer-Gideon syndrome, prenatal diagnosis of, 498

Laparoscopy, in infertility evaluation, 397

Large granular lymphocytic leukemia, flow cytometric analysis in, 262

Latex agglutination test, in coccidioidomycosis, 545

- in cryptococcosis, 546

- in HIV infection, 314

- in phosphatidylglycerol determination, 611

- in streptococcal infections, 526

Lecithin-to-sphingomyelin ratio, in fetal lung maturity assessment, 609-611

Legal issues. See also *Ethical and legal considerations*.

- in laboratory management, 850-851

- in transfusion medicine, 819-833

- AIDS litigation, 819-820

- liability protection, 822-831

- liability theories in, 820-831

- negligence, 821

- professional standard of care, 821-822

- strict products liability and warranty, 820-821

Legislative issues. See *Regulatory and legislative issues*.

- Leishmaniasis, screening for, in blood donors, 676
- Leukapheresis, in pregnancy, 594
- Leukemia(s), acute lymphoblastic, minimal residual cells from, detection of, 139-145
- acute myelogenous, minimal residual cells from, detection of, 145
- after bone marrow transplantation, detection of, 123-124
- chronic myelogenous, minimal residual cells from, detection of, 133-139
- diagnosis of, molecular probe techniques in, 114-115
- flow cytometric analysis in, 258, 260, 262
- in blood donors, guidelines for, 678
- platelet transfusion in, 660
- Leukocyte(s), in transfusion components, reduction of. See *Leukodepletion*.
- treatment of, for microbial inactivation, 788-789, 791-792
- integrins associated with, 219, 229
- Leukocyte adhesion deficiency, vs. granulomatous disease, 285, 287
- Leukodepletion, of transfusion components, 711-721
- in HLA alloimmunization prevention, 711-713
- in immune modulation prevention, 716-719
- in microbial removal, 791-792
- in nonhemolytic reaction prevention, 715-716
- in pulmonary complication prevention, 719-720
- in viral inactivation, 713-715
- storage of, bacterial growth during, 719
- Licensure, of blood banks, 836-837
- Liley curve, in hemolytic disease of newborn monitoring, 559-560
- Linkage analysis, 449-462
- counseling and, 458-460
- definitions in, 450
- gene mapping methods in, 450-458
- comparison of, 457-458
- family studies, 451-455
- for localization of disease gene, 455-457
- gene-dosage, 455-456
- in situ hybridization, 456-457
- LOD score, 451-454
- markers in, 454-455
- somatic cell hybridization, 457
- in cystic fibrosis, 458-459
- in Human Genome Initiative project, 460
- positive linkage disequilibrium in, 459
- recombination fraction in, 450
- syntenic loci in, 450
- Listeria monocytogenes* infection, in recurrent spontaneous miscarriage, 405
- prenatal diagnosis of, 526-527
- Livedo reticularis, in antiphospholipid antibody syndrome, 45-46
- Liver, autoimmune diseases of, 25-40
- chronic active hepatitis, 26-34
- primary biliary cirrhosis, 34-37
- primary sclerosing cholangitis, 37-38
- dysfunction of, plasma transfusion in, 663-664
- transplantation of, rejection markers in, 105-108
- Liver kidney microsomal antibodies, in chronic active hepatitis, 26, 29-32
- LOD score method, in linkage analysis, 451-454
- Lung cancer, paraneoplastic syndrome in, autoantibodies in, 64, 77-78
- Lung injury, in transfusion, leukocyte-depleted products and, 719-720
- Lung maturity, fetal, assessment of, 603-620
- foam-stability assay, 614-615
- lamellar body number density distribution, 616-618
- lecithin-to-sphingomyelin ratio method, 609-610
- optical absorbance methods, 612-614
- phospholipid determination, 610-612
- problems in, 603-606
- surface tension measurement, 614
- surfactant microviscosity measurement, 615-616
- surfactant production and, 606-607
- Lupus anticoagulant, cofactor requirements for, 50
- familial, 43
- in neurologic disease, 75
- in recurrent spontaneous miscarriage, 407
- incidence of, 42-43
- Lupus erythematosus, drug-induced, antibodies in, 8-9
- systemic. See *Systemic lupus erythematosus*.
- Luteal phase assessment, in infertility evaluation, 396-397
- Luteinizing hormone, assessment of, in infertility evaluation, 397-398, 402
- surge in, in ovulation prediction, 395
- Lyme disease, prenatal diagnosis of, 524-525



- Lymphocyte(s), activation of, serum markers for. See *Transplantation, rejection markers in*.
- CD antigens of, monoclonal antibodies to, in flow cytometry, 247
- flow cytometric analysis of. See *Flow cytometry, in lymphocyte marker analysis*.
- Lymphoma, flow cytometric analysis in, 260
- in blood donors, guidelines for, 678
- minimal residual cells from, detection of, 146
- Lymphopheresis, in pregnancy, 594
- Lymphoproliferative disorders, diagnosis of, molecular probe techniques in, 115
- Lysis, blood, for flow cytometry, 266-268
- Lysosomal storage disorder, Tay-Sachs disease as model for. See *Tay-Sachs disease*.
- Major histocompatibility complex antigens, in parentage analysis, 627-628, 633
- sharing of, in recurrent spontaneous miscarriage, 407-408
- Malaria, organisms causing, in blood transfusion components, inactivation of, 788
- prenatal diagnosis of, 542
- Malignancy. See *Cancer*.
- Mapping, gene. See under *Linkage analysis*.
- Markers, cell proliferation. See *Cell proliferation markers*.
- for congenital disease. See also *Blood group markers*.
- alpha-fetoprotein as, 481-492
- in linkage analysis, 454-455
- in transplantation rejection. See under *Transplantation*.
- lymphocyte. See *Flow cytometry, in lymphocyte marker analysis*.
- Me autoantigen and autoantibody, 17-18
- Medical history, in blood donor screening, 672-673, 677-678
- Medical record, consensable, 383-386
- Medical waste disposal, regulations on, 841
- Medicare, transfusion reimbursement policy of, 838-839
- Melanoma, immunotherapy in, monoclonal antibodies in, 203-205, 208-211, 213
- integrins associated with, 219, 221-222
- Merocyanine 540 treatment, of transfusion components, 796
- Metabolism, fetal, assessment of, 517-518
- inborn errors of, Tay-Sachs disease as model for. See *Tay-Sachs disease*.
- Metastasis, cell proliferation markers and, 166-168, 182-184
- inhibition of, integrin antagonists in, 230
- Methoxypsoralen treatment, of transfusion components, 795-796
- Methylene blue treatment, of transfusion components, 797
- 4-Methylumbelliferyl-beta-D-N-acetylglucosamine-6-sulfate, in hexosaminidase A detection, 468
- 4-Methylumbelliferyl-beta-D-N-acetylglucosaminide, in hexosaminidase A detection, 467-468
- Mi-2 antigen, antibodies to, in polymyositis/dermatomyositis, 12
- Microaggregates, reduction of, in leukocyte-depleted transfusion components, 719-720
- Microbial inactivation, in transfusion components, 787-803
- antimicrobial drugs in, 793-794
- chemical methods in, 793
- filtration in, 791-792
- goals of, 788-790
- irradiation in, 750-751, 794-795
- limitations of, 790
- photoinactivation in, 795-797
- solvent/detergent treatment in, 798
- targets for, 788
- thermal processes in, 791
- washing in, 792-793
- Microfibrillar collagen, in hemostasis, 777
- Microhemagglutination assay, for syphilis, 529-530
- Microscopy, in borreliosis, 524-525
- in coccidioidomycosis, 545
- in cryptococcosis, 546
- in fetal lung maturity assessment, 617
- in listeriosis, 526
- in syphilis, 530
- Microviscosity test, of amniotic fluid, in fetal lung maturity assessment, 615-616
- Miller-Dieker syndrome, prenatal diagnosis of, 456, 498
- Minisatellite sequences, in parentage analysis, 631
- Miscarriage, recurrent, definition of, 393
- evaluation of, 404-408
- Mixed connective tissue disease, autoantibodies in, 9-10

- Mixed lymphocyte culture reaction, in recurrent spontaneous miscarriage, 408
- MNS antigens, in hemolytic disease of newborn, 557
- in parentage analysis, 621-623
- Molecular probes, in bone marrow transplantation. See under *Bone marrow transplantation*.
- MoM (multiple of median value), in alpha-fetoprotein measurement, 485-489
- Monoclonal antibodies, in cancer immunotherapy, 201-216
- bispecific, 205-207
- directed to growth factor receptors, 210-211
- effector cell activation in, 202-205
- effector cell redirection to tumor sites by, 205-207
- genetically engineered, 211-213
- toxic agent conjugation by, 207-210
- in cell cycle analysis, 179
- in flow cytometry, of lymphocyte markers, 246-247, 263-266
- Monocyte monolayer assay, in hemolytic disease of newborn, 562
- Monosomy, in recurrent spontaneous miscarriage, 406
- Mosaicism, prenatal diagnosis of, 507
- Mouse/human chimeric anti-GD2 antibody ch14.18, in cancer immunotherapy, 203-205
- Multilocus probes, in parentage analysis, 631-633
- Multiple of median value, in alpha-fetoprotein measurement, 485-489
- Multiple-organ failure, transfusion in, 661, 663-664
- Multiple sclerosis, in blood donors, guidelines for, 678
- plasmapheresis in, 600
- Mural granulosa cells, removal in vitro fertilization, 417
- Myasthenia gravis, in blood donors, guidelines for, 678
- plasmapheresis in, 596-597, 600
- Mycobacterium tuberculosis*, prenatal detection of, 527
- Mycoplasma hominis*, identification of, in infertility evaluation, 399, 402
- in recurrent spontaneous miscarriage, 405-406
- prenatal, 528-529
- Mycosis fungoides, flow cytometric analysis in, 262
- Myeloma, in blood donors, guidelines for, 678
- Myeloperoxidase, antineutrophil cytoplasmic autoantibody recognition of, 85-87, 89-92, 94
- deficiency of, defective respiratory burst in, 285, 287
- Myeloproliferative syndrome, aplastic, diagnosis of, molecular probe techniques in, 115
- NADPH oxidase, component genes of, characterization of, 293, 295-299
- respiratory burst and, defective, 280-281, 284-285
- normal, 277, 279-280
- regulation of, 279-280
- Negligence, in transfusion medicine, 821
- Neisseria gonorrhoeae*, identification of, in infertility evaluation, 398-399, 402
- prenatal, 528
- Neonates. See *Infants, newborn*.
- Neopterin, as transplantation rejection marker, 101-103
- analysis for, 102-103
- heart, 106
- kidney, 104-105
- liver, 105-106
- Neural tube defects, acetylcholinesterase detection in, 485
- Neuroblastoma, immunotherapy in, monoclonal antibodies in, 203-205, 212-213
- Neurofilament, antibodies to, in neurologic disease, 77
- Neurologic disease, autoantibodies in. See under *Autoantibodies*.
- in antiphospholipid antibody syndrome, 46
- Neuronal gangliosides. See *Gangliosides*.
- Neuronal proteins, antibodies to, in neurologic disease, 62-64
- Neutropenia, in hemolytic disease of newborn, 564
- Neutrophil(s), autoantibodies to, 91-92
- Neutrophil cytoplasmic antigen, autoantibodies to. See *Antineutrophil cytoplasmic autoantibodies*.
- Neutrophil glucose-6-phosphate dehydrogenase deficiency, defective respiratory burst in, 284-285
- Newborn. See under *Infants*.
- Nitroblue tetrazolium reduction test, in granulomatous disease, 298
- Nonoxynol-9 treatment, of transfusion components, 793
- Nonstress test, antepartum, in hemolytic disease of newborn, 563

- Nontreponemal antibody tests, for syphilis, 529
- NOR-90 antigen, antibodies to, in scleroderma, 13
- Northern blot test, in granulomatous disease, 296
- Nuclear lamins, antibodies to, in rheumatic disease, 16-17
- Nuclear pore complexes, antibodies to, in rheumatic disease, 17
- Nuclear ribonucleoprotein, antibodies to, in SLE, 3-4
- Nucleolar antigens, antibodies to, in scleroderma, 13
- Nucleolar organizer regions, in cell proliferation measurement, 179-180, 192
- Occupational Safety and Health Administration, transfusion medicine regulation by, 840-841
- Odds ratio, in paternity inclusion calculation, 629
- Oligonucleotide ligase amplification, in parentage analysis, 633-634
- Oligonucleotide probes, in Tay-Sachs disease assessment, 472
- Oncogenes, 164, 166
- Oncology. *See Cancer.*
- Oocyte(s), genetic testing of, 495-496  
preparation for in vitro fertilization, 415-421
- Oocyte-cumulus complex, 416-419
- Optical absorbance method, in fetal lung maturity assessment, 612-614
- OSHA (Occupational Safety and Health Administration), transfusion medicine regulation by, 840-841
- Ovulation, documentation of, 393-396
- Ozone treatment, of transfusion components, 793
- p24 antigen, assay for, 533  
in HIV infection, antibodies to, 308, 310  
direct detection of, 318
- Papillomavirus infections, prenatal diagnosis of, 538-539
- Paraformaldehyde treatment, of transfusion components, 793
- Paraneoplastic syndromes, autoantibodies in, 62-64, 77-78
- Parasites, in blood transfusion components, testing for, 763  
infestations of. *See specific infection.*
- Parentage analysis, 621-641
- blood groups in, 621-625
- blood protein polymorphisms in, 625-627
- Duffy antigens in, 623
- electrophoresis in, 625-627
- ethical problems in, 634-636
- immunoglobulin allotyping in, 625
- indications for, 636
- Kell antigens in, 623
- Kidd antigens in, 623
- major histocompatibility antigens in, 627-628, 633
- methods for, 764
- nucleotide sequence variations in, 630-633
- paternity inclusion calculations in, 628-630
- polymerase chain reaction in, 633
- restriction fragment length polymorphisms in, 630-631, 633
- technical issues in, 634-636
- variable number of tandem repeats in, 631-633
- with absent parent, 636
- with unborn child, 636
- Parvovirus B19, in blood transfusion components, testing for, 763
- infection with, prenatal diagnosis of, 511-512, 537
- Paternity determination. *See Parentage analysis.*
- PCNA. *See Proliferating-cell nuclear antigen.*
- Pediatric patients. *See also Infants.*
- HIV testing in, 322-324
- plasma transfusion in, 664-665
- platelet transfusion in, 662-663
- transfusion in, 746-748
- Pen antigens, in neonatal alloimmune thrombocytopenia, 581
- Peptides, as antigens in HIV testing, 313-314
- Percoll gradient separation, of sperm, for in vitro fertilization, 412-413
- Peridinin chlorophyll, in flow cytometry, 246
- Personnel, management of. *See Workload recording method.*
- Phagocytosis, respiratory burst in, defective, 280-281, 284-285  
normal, 277, 279-280  
regulation of, 279-280
- Philadelphia chromosome, detection of, in bone marrow, 133-139
- Phosphate, in embryo culture media, 423
- Phosphatidylglycerol, in pulmonary surfactant, determination of, 610-612
- Phospholipids, antibodies to. *See Antiphospholipid antibodies.*
- in pulmonary surfactant, 606-607

- determination of, 610-611
- Photoinactivation, of microbes, in  
transfusion components, 795-797
- Phycobiliproteins, in flow cytometry, 245-246, 264-266
- PI<sup>A1</sup> antigens, in neonatal alloimmune thrombocytopenia, 580-581, 583
- PI<sup>A2</sup> antigens, in neonatal alloimmune thrombocytopenia, 580-581
- PL-7 antigen (threonyl tRNA synthetase), antibodies to, in polymyositis, 11
- PL-12 antigen (alanyl tRNA synthetase), antibodies to, in polymyositis, 11
- Plasma, fresh frozen, in plasmapheresis, 599
- transfusion of, guidelines for, 772-773
- immunosuppression in, 728-729
- indications for, 663-665
- volume of, estimation of, 588-589
- Plasmacytoid lymphocytic leukemia, flow cytometric analysis in, 260
- Plasmapheresis, donor screening for, 681
- in blood disorders, 594-598
- in dermatologic disease, 601
- in gastrointestinal disease, 601
- in hemolytic disease of newborn, 568-569, 596-598
- in hemolytic uremic syndrome, 594-596
- in myasthenia gravis, 597
- in neurologic disorders, 599-600
- in renal disease, 600
- in rheumatologic disease, 600
- replacement solutions for, 598-599
- technique for, 592
- uses of, 774
- volume calculations for, 588-592
- Plasmodium*, prenatal detection of, 542
- Platelet(s), consumption of, transfusion in, 661-662
- destruction of, transfusion in, 660-661
- dysfunction of, transfusion in, 662
- transfusion of, guidelines for, 772
- in neonatal alloimmune thrombocytopenia, 584
- indications for, 659-663
- Platelet antigens, alloimmunization to, neonatal thrombocytopenia in, 577-586
- prevention of, in transfusion, 711-713
- identification of, in neonatal alloimmune thrombocytopenia, 581-583
- prenatal, 514
- phenotyping of, 765
- Plateletpheresis, donor screening for, 681
- in pregnancy, 594
- uses of, 774-775
- Ploidy, clinical significance of, prognostic, 180-182, 186-190
- therapeutic, 186-191
- flow cytometry analysis of, 174-177
- PM-Scl antigen, antibodies to, in polymyositis/dermatomyositis, 11
- in scleroderma, 13
- Poly (ADP-ribose) polymerase, antibodies to, in rheumatic disease, 17
- Polymerase chain reaction, in bone marrow minimal residual disease, acute lymphoblastic leukemia, 139-143
- chronic myelogenous leukemia, 135-139
- contamination in, 131-132
- immunoglobulin rearrangement detection, 144
- nested primers in, 136-137
- quantitation in, 132-133
- reproducibility of, 132
- T-cell receptor rearrangement detection, 144-145
- in borreliosis, 525
- in chlamydial infection, 538
- in cytomegalovirus infection, 532
- in granulomatous disease, 297
- in hematology, 764-765
- in herpes simplex virus infection, 535
- in HIV infection, 319-320, 533
- in human leukocyte antigen analysis, 763-764
- in infectious agent detection, 762-763
- in listeriosis, 526-527
- in parentage analysis, 633, 764
- in Tay-Sachs disease, 472-474
- in transfusion medicine, 759-762
- in trypanosomiasis, 543
- in tuberculosis, 527
- Polymyositis, autoantibodies in, 11-12
- Polyneuropathy, chronic inflammatory demyelinating, plasmapheresis in, 600
- Polyspecific antiglobulin reagent, in antibody screening, for transfusion, 690
- Postcoital test, in infertility evaluation, 396
- Postoperative erythroderma, in graft-versus-host disease, 749
- Prader-Willi syndrome, prenatal diagnosis of, 497-498
- Prednisone, in antiphospholipid antibody syndrome, 47
- in chronic active hepatitis, 34
- Pregnancy. See also *Fetus*.
- alpha-fetoprotein testing in, 481-492
- hemapheresis in, 587-602
- calculations for, 588-592
- nontreatment, 592-593
- technology for, 587-588
- therapeutic, 593-601

Pregnancy (*Continued*)

- HIV testing in, 323-324
- losses in, in antiphospholipid antibody syndrome, 44-45, 47
- multiple, alpha-fetoprotein results and, 487
- red cell alloimmunization in. See *Hemolytic disease of newborn*.
- Tay-Sachs disease testing in. See *Tay-Sachs disease*.
- Premature infants, transfusion in, 746-748
- Prenatal diagnosis. See also *Fetus, diagnosis of disorders in; Genetic disease*.
  - of granulomatous disease, 297-299
  - of HIV infection, 323-324
- Primary biliary cirrhosis, 34-37
- Procainamide, lupus erythematosus induced by, 8-9
- Productivity, in workload recording method, 345-347
- Professional standard of care, in transfusion medicine, 821-822
- Proficiency testing programs, 850-851
- Progesterone, assessment of, in infertility evaluation, 398
  - in recurrent spontaneous miscarriage, 405, 408
- Prolactin, assessment of, in infertility evaluation, 397-398, 402
  - in recurrent spontaneous miscarriage, 405
- Proliferating cell antigens, in cell cycle analysis, 190-192
  - types of, 179
- Proliferating cell nuclear antigen, antibodies to, in SLE, 6
- Proliferating cell nuclear antigen/cyclin, quantitation of, 192
- Proliferative index, in cell cycle analysis, 176
- Promethazine hydrochloride, in hemolytic disease of newborn, 568
- Propidium iodide, in cell cycle analysis, 174
- Prostaglandins, in immunosuppression, in transfusion, 730
- Protease inhibitors, in hemostasis, 776
- Protein, in embryo culture media, 422
- Protinin, in hemostasis, 776
- Psoralen derivative treatment, of transfusion components, 795-796
- Pulmonary insufficiency, in transfusion, leukocyte-depleted components and, 719-720
- Pulmonary surfactant. See *Lung maturity, fetal*.
- Pulse exposure techniques, in cell cycle analysis, 173

- Pyrimidines, halogenated, in cell cycle analysis, 179, 190
- Pyruvate, in embryo culture media, 422
- Pyruvate dehydrogenase complex, subunits of, antigenic activity of, in primary biliary cirrhosis, 35-36

## Quality assurance, 805-817

- audits in, 814-816
- current status of, 809-812
- evolution of, 806-812
- in transfusion, 706
  - FDA role in, 838
  - tests required for, 805-806
- product audits in, 815-816
- quality control in, 813
- quality functions in, 813
- quality improvement in, 813
- quality planning in, 813-814
- redefining of, 812-814
- surveys in, 815
- total (organization-wide), 809-812
- traditional, 808
- Quintana v United Blood Services*, 824-828

- RA33 antigen, antibodies to, in rheumatoid arthritis, 14-15
- Racial factors, in alpha-fetoprotein results, 487
- Radiation, of transfusion components, for microbial inactivation, 794-795
  - in graft-versus-host disease prevention, 750-751
- Radioimmunoassay, for alpha-fetoprotein, 484-485
  - for hormones, in infertility evaluation, 397
  - for neopterin, 102-103
  - in parvovirus B19 infection, 537
- Radioimmunoprecipitation antibody assay, in HIV testing, 316-317
- Radioisotope studies, in cell cycle analysis, 172-173
- Radiometry, in hemolytic disease of newborn monitoring, 561
- Radionuclides, in cancer immunotherapy, monoclonal antibody conjugation to, 207
- Rapid latex agglutination screening assays, for HIV, 314
- Rapid plasma reagin card test, for syphilis, 529
- Reagin tests, for syphilis, 529
- Recombination fraction, in linkage analysis, 450

- Records, review of, as transfusion safety precaution, 688-689
- Recurrent respiratory papillomatosis, 539
- Red cells, alloimmunization with. See *Hemolytic disease of newborn*.
- exchange of, in pregnancy, 593-594
- transfusion of, alternatives to, 658
- guidelines for, 771-772
- indications for, 655-658
- safety in, 685-700. See also *Leukodepletion*.
- ABO group determination in, 686-687, 689
- antibody screening in, 687-688, 690-692
- crossmatching in, 692-694
- factors in, 685
- records review in, 688-689
- Rh group determination in, 686-687, 689
- specimen storage in, 688
- transfusion reaction and, 694-696
- Registry, for blood donors, 681-682
- Regulatory and legislative issues, in transfusion medicine, 835-844
- American Association of Blood Banks role in, 841-842
- biohazardous waste disposal, 841
- Food and Drug Administration role in, 836-838
- Health Care Financing Administration role in, 838-840
- Occupational Safety and Health Administration role in, 840-841
- shipment of blood and specimens, 841
- Rejection, allograft. See *Transplantation, rejection markers in*.
- Reproductive medicine, alpha-fetoprotein markers in, 481-492
- artificial insemination in, 430-436
- congenital disease screening in, 481-492
- cordocentesis in, 503-522, 563-564
- cryopreservation in, 430-431
- ethics of, 429-448
- exploitation in, 439-442
- extrauterine embryo status in, 441-445
- fetal lung maturity assessment in, 603-620
- gamete donation, 429-448
- gamete intrafallopian transfer in, 430-432
- genetic disease prediction in, cytogenetics in, 493-502
- linkage analysis in, 449-462
- Tay-Sachs disease, 463-480
- hemapheresis in, 587-602
- in vitro fertilization in, 411-428, 429-448, 430-432, 441-445
- inborn errors of metabolism screening in, 463-480
- infection diagnosis in, fetal, 523-552
- infertility evaluation in, 393-410
- legal aspects of, 429-448
- linkage analysis in, 449-462
- neonatal alloimmune thrombocytopenia and, 577-586
- parentage analysis in, 621-641
- red cell antigen immunity in, 553-576
- spontaneous miscarriage evaluation in, 404-408
- surrogate motherhood in, 432-441
- Tay-Sachs disease screening in, 463-480
- transfusion in, fetal, 553-576
- zygote intrafallopian transfer in, 430-432
- Repulsion, in linkage analysis, 450
- Respiratory burst, in phagocytosis. See under *Phagocytosis*.
- Respiratory distress syndrome, neonatal, lung maturity in, 603-630
- Restriction fragment length polymorphisms, in bone marrow transplantation testing, 115-119
- in linkage analysis, 455
- in parentage analysis, 630-631
- in Tay-Sachs disease assessment, 472-474
- Reticuloendothelial blockade, in immunosuppression, in transfusion, 730-731
- Retinoblastoma, prenatal diagnosis of, 456, 498
- Retinopathy, paraneoplastic, autoantibodies in, 64
- Rh antigens, alloimmunization to. See *Hemolytic disease of newborn*.
- in parentage analysis, 623
- Rh blood groups, determination of, for transfusion, 686-687, 689
- Rheumatoid arthritis, autoantibodies in, 13-15
- in blood donors, guidelines for, 678
- Rheumatoid arthritis-associated nuclear antigen, antibodies to, 13-14
- Rheumatologic disease, autoantibodies in. See under *Autoantibodies*.
- plasmapheresis in, 600
- Ri antigen, antibodies to, in paraneoplastic syndrome, 63-64
- Ribosomal ribonucleoprotein, antibodies to, in mixed connective tissue disease, 9-10
- in SLE, 5-6
- RNA detection techniques, in HIV testing, 319-320
- RNA polymerase 1, antibodies to, in scleroderma, 13

- Rubella, prenatal diagnosis of, 510-511, 533-534
- S-phase fraction, in cell cycle analysis, 176  
prognostic implications of, 181-182
- Sabin-Feldman dye test, in toxoplasmosis, 508, 541
- Safety precautions, in flow cytometry, 274  
in transfusion. See also *Blood donors*,  
  *screening of*.  
  infectious complication prevention in,  
    701-710  
    appropriate use in, 706  
    bacterial contamination and, 706  
    blood testing in, 703-706  
    donor selection in, 701-703  
    microbial inactivation in, 787-803  
    transfusion-transmitted disease re-  
      porting in, 706-707  
  of red cells, 685-700
- Salpingitis, in infertility, 398-399
- ScL-70 antigen, antibodies to, in  
  scleroderma, 12-13
- Scleroderma, autoantibodies in, 12-13
- Screening, of blood donors. See under  
  *Blood donors*.
- Selection theory, of immunosuppression,  
  in transfusion, 730
- Semen analysis, in infertility evaluation,  
  400-402
- Sensory neuropathy, paraneoplastic,  
  autoantibodies in, 64
- Sequence-specific oligonucleotide probes,  
  in bone marrow transplantation  
  testing, 115-117
- Shake test (foam-stability assay), in fetal  
  lung maturity assessment, 614-615
- Shell vial culture spin-amplification  
  technique, in cytomegalovirus  
  detection, 531  
  in herpes simplex virus detection, 535
- Shingles, prenatal diagnosis of, 511
- Sicca syndrome, in primary biliary  
  cirrhosis, 35
- Sickle cell disease, cytopheresis in, 593-  
  594  
  prenatal diagnosis of, 513
- Silva v Southwest Florida Blood Bank, Inc.*,  
  824, 828-831
- Sjögren's syndrome, autoantibodies in,  
  10-11
- SLE. See *Systemic lupus erythematosus*.
- Sm antigen, antibodies to, in SLE, 3-4
- Smith-Magenis syndrome, prenatal  
  diagnosis of, 498
- Smooth muscle antibodies, in chronic  
  active hepatitis, 26-27, 29
- Sodium deoxycholate treatment, of  
  transfusion components, 798
- Soluble liver antigen autoantibodies, in  
  chronic active hepatitis, 27, 32-33
- Solvent/detergent treatment, of  
  transfusion components, 798
- Somatic cell hybridization, in linkage  
  analysis, 457
- Southern blot, in bone marrow minimal  
  residual disease, 130, 135  
  in granulomatous disease, 296
- Specimen storage, in blood compatibility  
  testing, 688
- Sperm, acrosome reaction of, 414-415  
  antibodies to, in infertility, 399-400, 402  
  capacitation of, 413-414  
  donation of, ethical aspects of. See un-  
    der *Ethical and legal considerations*.  
  evaluation of, in infertility, 400-404  
  preparation for in vitro fertilization,  
    411-415
- Sperm mixed agglutination reaction test,  
  400, 402
- Sperm penetration assay, 402-403
- Sphingomyelin, in fetal lung maturity  
  assessment, 609-611
- SS/A-Ro antigen, antibodies to, detection  
  of, 15  
  in rheumatic disease, 4, 6-7  
  in Sjögren's syndrome, 10-11
- SS/B-La antigen, antibodies to, in  
  Sjögren's syndrome, 10-11  
  in SLE, 4
- Static cytophotometry, in DNA content  
  analysis, 177-180
- Statistical mechanics, analogies to test  
  selection decision making, 372-375
- Streptococcal infections, prenatal  
  diagnosis of, 525-526
- Sulfonated aluminum phthalocyanine  
  treatment, of transfusion  
  components, 796
- Superoxide anion, release of, in  
  phagocytosis. See *Phagocytosis*,  
  *respiratory burst in*.  
  sperm damage by, 414-415
- Surface tension, of amniotic fluid, in fetal  
  lung maturity assessment, 614
- Surfactant, pulmonary. See *Lung maturity*,  
  *fetal*.
- Surrogate motherhood, ethical and legal  
  considerations in, 432-441
- Swim-up procedure, for in vitro  
  fertilization, 412
- Syntenic genes, definition of, 450
- Syphilis, biologic false-positive serologic  
  test for, incidence of, 43  
  in recurrent spontaneous miscarriage,  
    405



- prenatal diagnosis of, 529-530
- Systemic lupus erythematosus,
  - autoantibodies in, 2-8
  - antinuclear antibody negative type, 6-7
  - in disease classification, 7-8
  - psychosis and, 76
  - subacute cutaneous, 6-7
  - to heat shock protein 90, 6
  - to Ki antigen system, 5, 76
  - to Ku antigen system, 4-5
  - to native DNA, 2-3
  - to nuclear ribonucleoproteins, 3-4
  - to phospholipids, 49
  - to proliferating cell nuclear antigen, 6
  - to ribosomal ribonucleoprotein, 5-6
  - to Sm antigen, 3-4
  - to SS-A/Ro and SS-B/La antigens, 4, 6-7
  - in blood donors, guidelines for, 678
- Sézary syndrome, flow cytometric analysis in, 262
- T-cell lymphoproliferative disease, flow cytometric analysis in, 260, 262
- T-cell prolymphocytic leukemia, flow cytometric analysis in, 262
- T-cell receptor rearrangements, in leukemia, 144-145
- Tay-Sachs disease, 463-480
  - adult-onset, 466
  - beta-hexosaminidase A detection in, 467-468
  - biochemical defect in, 466-467
  - carriers of, identification of, 464-465
  - clinical course of, 465-466
  - inheritance of, 464
  - juvenile, 466
  - molecular epidemiology of, 470
  - pathophysiology of, 465-466
  - populations at risk for, 465
  - prenatal diagnosis of, 468-469
  - testing for, ethical considerations in, 476-477
  - molecular methodology in, 469-470, 472-474
  - results of, 477
  - screening programs in, 474-476
- Temperature monitoring, in ovulation documentation, 393-395
- Test results, reporting methods for, 852-853
- Test selection, 353-388
  - for consensible medical record, 383-386
  - NP-complete problems in, 380-383
  - primary classifications for, 355-370
    - data acquisition for, 356
    - dendrograms in, 361
    - entropy in, 372-375
    - indicative sentences in, 357-358
    - information loss in, 362-363
    - likelihood identification in, 376-377
    - linkage clustering in, 363-370
    - logical comprehension in, 378
    - mapping in, 361
    - matrices in, 358
    - Port Royal logic in, 370-375
    - probability in, 361
    - realistic comprehension in, 378-379
    - relative frequency classification in, 376-377
    - scaling in, 361-363
    - separatory clustering in, 363-370
    - statistical mechanics analogies, 372-375
    - sufficiency of information in, 377-378
    - theoretic comprehension in, 379-380
    - truth tables in, 358-362
    - uncertainty in, 361
    - usefulness in, 377-378
    - variables in, 357-358
  - quality improvement in, 354
- Testosterone, assessment of, in infertility evaluation, 398, 402
- Thalassemia, prenatal diagnosis of, 513
- Thermal inactivation, of transfusion components, for microbial inactivation, 791
- Thin-layer chromatography, in fetal lung maturity assessment, 609-611
- Threonyl tRNA synthetase, antibodies to, in polymyositis, 11
- Thrombocytopenia, in antiphospholipid antibody syndrome, 45, 47
  - in hemolytic disease of newborn, 564
  - in thrombotic thrombocytopenia purpura, plasmapheresis in, 594-596
- neonatal alloimmune, 577-586
  - clinical manifestations of, 578
  - diagnostic testing in, 581-583
  - differential diagnosis of, 578-579
  - epidemiology of, 577-578
  - immunologic aspects of, 579-581
  - management of, 583-585
  - platelet transfusion in, 659-663
  - prenatal diagnosis of, 514
- Thrombosis, in antiphospholipid antibody syndrome, 44, 46-47
  - inhibition of, integrin antagonists in, 230
- Thrombotic thrombocytopenic purpura, plasmapheresis in, 594-596
  - platelet transfusion in, 662

- Thymidine labeling method, in cell cycle analysis, 173  
 prognostic implications of, 180-181
- Thyroid hormones, assessment of, in infertility evaluation, 398  
 in recurrent: spontaneous miscarriage, 405
- Thyroid-stimulating hormone, assessment of, in infertility evaluation, 397-398
- Tissue culture, in infertility evaluation, 399
- To antigens, antibodies to, in scleroderma, 13
- Toxins, monoclonal antibody-drug conjugates with, 207-209
- Toxoplasmosis, prenatal diagnosis of, 507-510, 539-542
- Transfusion. See also *Hemapheresis*; *Plasmapheresis*.  
 alternatives to, 658  
   apheresis components as, 774-775  
   hemostatic agents as, 775-778  
   autologous, 658, 778-783  
   indications for, 779  
   Medicare reimbursement policy on, 838-839  
   postoperative infection and, 726  
   preoperative donation of, 782  
   with salvaged blood, 779-780  
 blood storage before, 706  
 cancer recurrence and, 717, 724-726  
 chronic, immunosuppression in, 726-727  
 committed designated donation for, 783  
 crossmatching in, 692-694  
 directed donation for, 681, 780  
 disease transmission in, prevention of, 701-710  
   microbial inactivation in, 787-803  
   donor screening for, 669-683, 701-706  
   from multiple donors, minimization of, 747-748  
   graft-versus-host disease in, 718, 749-751  
   hemoglobin level trigger for, 656-658  
   hemolytic reactions in, 694-696  
 homologous blood exposure limitation in, 771-785. See also *Transfusion*, *autologous*.  
   alternatives to, 775-778  
   apheresis products in, 774-775  
   guidelines for, 771-773  
   hemostatic agents in, 775-778  
   individualized plans for, 781-783  
   preoperative hemostasis evaluation in, 773-774  
 immunosuppression in, 723-741  
   leukocyte-depleted components and, 716-719  
   in cancer recurrence, 724-726  
   in Crohn's disease, immunosuppressive effects of, 727-728  
   in neonates, 746-748  
   in pediatric patients, 746-748  
   of platelets, 662-663  
   in transplantation, immunosuppression in, 716-718, 723-724  
   indications for, 655-667  
   individual considerations in, 781-783  
   intrauterine intravascular, in alloimmune thrombocytopenia, 584  
   in hemolytic disease of newborn, 566-568  
 irradiation of components for, for microbial inactivation, 794-795  
   in graft-versus-host disease prevention, 750-751  
 Jehovah's Witness patients and, 778, 780-781  
 legal issues in, 819-833  
 legislative issues in, 835-844  
 leukocyte-reduced components in, 711-721  
 massive, 743-745  
   in small children, 748  
 Medicare reimbursement for, 838-839  
 microaggregate removal in, 719-720  
 microbes in, inactivation of, 787-803  
   testing for, 762-763  
 minimal-exposure, 781-782  
 of antithrombin III, 751-753  
 of cryoprecipitate, guidelines for, 772  
   indications for, 663-665  
   limitations of, 772  
 of Factor VIII, 665  
 of fibrinogen, 665  
 of plasma, guidelines for, 772-773  
   immunosuppression in, 728-729  
   indications for, 663-665  
   limitations of, 772-773  
 of platelets, guidelines for, 772  
   in neonatal alloimmune thrombocytopenia, 584  
   indications for, 659-663  
   limitation of, 772  
 of red cells, alternatives to, 658  
   guidelines for, 771-772  
   indications for, 655-658  
   limitations of, 771-772  
   safety in, 685-700  
   of salvaged blood, 779-780, 782-783  
   of von Willebrand factor, 665  
   of whole blood, guidelines for, 773  
   indications for, 773  
   limitations of, 773  
 postoperative infection and, 726  
 preoperative hemostasis evaluation and, 773-774

- quality assurance in, 805-817  
 reactions to, 694-696  
   prevention of, leukocyte-depleted components in, 715-716  
 regulatory issues in, 835-844  
 safety in, 685-700  
   donor screening in, 669-683, 701-706  
   infectious complication prevention in, 701-710  
   microbial inactivation in, 787-803  
   salvaged autologous blood in, 782-783  
   special issues in, 743-757  
   testing approaches in, 759-770  
   trigger point for, 656-658  
 universal precautions in, 840-841
- Transplantation, bone marrow. *See Bone marrow transplantation.*
- immunosuppression in, from blood transfusion, 716-718, 723-724  
 rejection markers in, 99-111  
   heart, 106, 108-109  
   interleukin-2 soluble receptor, 103-104, 106-109  
   kidney, 104-107  
   liver, 105-108  
   neopterin, 101-106
- Trasylol (protinin), in hemostasis, 776
- Trauma, platelet consumption in, transfusion in, 662
- Treponema pallidum*, prenatal detection of, 529-530
- Treponemal antibody testing, for syphilis, 529-530
- Tri(n-butyl)phosphate treatment, of transfusion components, 798
- Trisomy, in recurrent spontaneous miscarriage, 406
- Trisomy 21, linkage analysis in, 456
- Trophoblast-lymphocyte cross-reactive antigens, in recurrent spontaneous miscarriage, 408
- Truth tables, in test selection, 358-362
- Trypanosoma cruzi*, in blood transfusion components, donor screening for, 676  
   testing for, 763
- Trypanosomiasis, prenatal diagnosis of, 543
- Tube precipitin test, in coccidioidomycosis, 545
- Tuberculosis, prenatal diagnosis of, 527
- Tumor(s). *See also Cancer.*  
   biology of, carcinogenesis, 164-168  
   growth kinetics, 168-169  
   heterogeneity, 168  
   metastasis. *See Metastasis.*  
   growth suppression in, monoclonal antibodies in, 210-211  
   recurrence of, from transfusion immunosuppression, 724-726
- Tumor markers. *See Cell proliferation markers.*
- Ultrasonography, efficacy of, in genetic disease detection, 500-501  
   in hemolytic disease of newborn, 562-563  
   in intrauterine transfusion, 566-567  
   in ovulation documentation, 395-396  
   in prenatal diagnosis, 494
- Ultraviolet light irradiation, of transfusion components, for microbial inactivation, 794-795  
   in graft-versus-host disease prevention, 750-751
- Umbilical cord, blood sampling from. *See Cordocentesis.*
- Unconjugated estriol, in Down syndrome screening, 489-490
- United Blood Services, Inc., litigation involving, 824-828
- Universal precautions, for blood handling, 840-841
- Ureaplasma urealyticum*, identification of, in infertility evaluation, 399, 402  
   in recurrent spontaneous miscarriage, 405-406  
   prenatal, 528-529
- Uremic syndrome, hemolytic, plasmapheresis in, 594-596
- Ursodesoxycholic acid, in primary biliary cirrhosis, 37  
   in primary sclerosing cholangitis, 38
- Vaccination, blood donation deferral after, 676-677
- Variable number of tandem repeats, in parentage analysis, 631-633
- Varicella-zoster virus infections, prenatal diagnosis of, 511, 536-537
- Veneral Disease Research Laboratory test, for syphilis, 529
- Vinblastine derivative-monoclonal antibody conjugate, in cancer immunotherapy, 209-210
- Viper venom peptides, as integrin antagonists, 230
- Viral infections. *See also specific disease.*  
   in transplant patients, indicators of, 105
- Viruses. *See also specific virus.*

Viruses (*Continued*)

- in blood transfusion components, inactivation of. See *Microbial inactivation*.
- testing for, 762-763
- Vitronectin, integrins associated with, 229
- von Willebrand factor, tests for, 764
- transfusion of, 665
- von Willebrand disease, prenatal diagnosis of, 513
- Warfarin reversal, plasma transfusion in, 663-664
- Washing, of transfusion components, for microbial removal, 792-793
- Waste, biohazardous, regulations on, 841
- Wegener's granulomatosis, autoantibodies in, 87, 89-91
- Weight, maternal, alpha-fetoprotein results and, 486-487
- Western blot test, in HIV testing, 314-316, 532
  - in Lyme disease, 524
  - in *Treponema pallidum* detection, 530
- Whole blood, transfusion of, guidelines for, 773
- Workload Productivity Comparison Program, 349
- Workload recording method, 339-352
  - applications of, 347-348
  - constant hour tracking in, 344
  - data collection in, 344-345
  - historical background of, 340-341
  - implementation of, 344-345
  - management and, 349
  - nonworkload activity tracking in, 343-344
  - principles of, 341-343
  - productivity ratio recommendations for, 345-347
  - time studies with, 343-344
  - units used in, 341-343
- Xenodiagnosis, of trypanosomiasis, 543
- Yersinia enterocolitica*, screening for, in blood donors, 676
- Yo antigen, antibodies to, in paraneoplastic syndrome, 62-63
- Yuk (Pen) antigens, in neonatal alloimmune thrombocytopenia, 581
- Zygote intrafallopian transfer (ZIFT), ethical and legal considerations in, 430-432

